POU2AF2/C11orf53 functions as a coactivator of POU2F3 by maintaining chromatin accessibility and enhancer activity.

POU2AF2/C11orf53 functions as a coactivator of POU2F3 by maintaining chromatin accessibility and enhancer activity.
复制标题

DOI:
10.1126/sciadv.abq2403
复制
发表时间:
2022-10-07
期刊:
影响因子:
13.6
通讯作者:
--
中科院分区:
综合性期刊1区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

小细胞肺癌(SCLC)约占所有肺癌的13%,常导致肿瘤快速生长、早期转移和获得性耐药。POU类2同源盒3(POU2F3)是丛生细胞识别的主要调节因子,它定义了缺乏神经内分泌标志物的SCLC-P亚型。在这里,我们已经鉴定了一个以前未鉴定的蛋白C11orf53,它与POU2F3在SCLC细胞系和患者样本中共同表达。在机制上,C11orf53直接与POU2F3相互作用,并被POU2F3招募到染色质中。C11orf53的缺失降低了增强子H3K27ac的水平和染色质的可及性,导致POU2F3依赖的基因表达减少。根据C11orf53的分子功能,我们将其命名为POU Class 2 Homeobox Associating Factor2(POU2AF2)。综上所述,我们的研究确定了一种新的POU2F3共激活子,并揭示了靶向POU2AF2/POU2F3异源二聚体在人小细胞肺癌中的治疗潜力。C11orf53是POU2F3的一种新的共激活剂,它对增强子活性、染色质可及性和小细胞肺癌细胞活力至关重要。
Small cell lung cancer (SCLC), accounting for around 13% of all lung cancers, often results in rapid tumor growth, early metastasis, and acquired therapeutic resistance. The POU class 2 homeobox 3 (POU2F3) is a master regulator of tuft cell identity and defines the SCLC-P subtype that lacks the neuroendocrine markers. Here, we have identified a previously uncharacterized protein, C11orf53, which is coexpressed with POU2F3 in both SCLC cell lines and patient samples. Mechanistically, C11orf53 directly interacts with POU2F3 and is recruited to chromatin by POU2F3. Depletion of C11orf53 reduced enhancer H3K27ac levels and chromatin accessibility, resulting in a reduction of POU2F3-dependent gene expression. On the basis of the molecular function of C11orf53, we renamed it as “POU Class 2 Homeobox Associating Factor 2” (POU2AF2). In summary, our study has identified a new coactivator of POU2F3 and sheds light on the therapeutic potential of targeting POU2AF2/POU2F3 heterodimer in human SCLC. C11orf53 is a new coactivator of POU2F3 that is critical for enhancer activity, chromatin accessibility, and SCLC cell viability.
DOI: 10.1016/j.omto.2021.02.004
发表时间: 2021-03-26
期刊: Molecular therapy oncolytics
影响因子: --
作者:
Schwendenwein A;Megyesfalvi Z;Barany N;Valko Z;Bugyik E;Lang C;Ferencz B;Paku S;Lantos A;Fillinger J;Rezeli M;Marko-Varga G;Bogos K;Galffy G;Renyi-Vamos F;Hoda MA;Klepetko W;Hoetzenecker K;Laszlo V;Dome B
通讯作者: Dome B
DOI: 10.1038/s41572-020-00235-0
发表时间: 2021-01-14
期刊: Nature reviews. Disease primers
影响因子: --
作者:
Rudin CM;Brambilla E;Faivre-Finn C;Sage J
通讯作者: Sage J
DOI: 10.1038/s41591-018-0034-6
发表时间: 2018-06
期刊: Nature medicine
影响因子: 82.9
作者:
Wang L;Zhao Z;Ozark PA;Fantini D;Marshall SA;Rendleman EJ;Cozzolino KA;Louis N;He X;Morgan MA;Takahashi YH;Collings CK;Smith ER;Ntziachristos P;Savas JN;Zou L;Hashizume R;Meeks JJ;Shilatifard A
通讯作者: Shilatifard A
DOI: 10.1158/0008-5472.can-21-1114
发表时间: 2021-09-15
期刊: Cancer research
影响因子: 11.2
作者:
Zhao Z;Szczepanski AP;Tsuboyama N;Abdala-Valencia H;Goo YA;Singer BD;Bartom ET;Yue F;Wang L
通讯作者: Wang L
DOI: 10.1101/gad.314815.118
发表时间: 2018-07-01
影响因子: 10.5
作者:
Huang YH;Klingbeil O;He XY;Wu XS;Arun G;Lu B;Somerville TDD;Milazzo JP;Wilkinson JE;Demerdash OE;Spector DL;Egeblad M;Shi J;Vakoc CR
通讯作者: Vakoc CR